Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 01/15/2026 | Q4 | $14.3B | -- | -- | $11.68 | -- |
| 10/14/2025 | Q3 | $14.3B | $32.2B | $12.25 | $10.63 | $1.62 |
| 07/16/2025 | Q2 | $13.6B | $31.2B | $10.91 | $9.62 | $1.29 |
| 04/14/2025 | Q1 | $14.7B | $31.4B | $14.12 | $12.29 | $1.83 |
| 01/15/2025 | Q4 | $12.5B | $31.8B | $11.95 | $8.29 | $3.65 |
| 10/15/2024 | Q3 | $11.8B | $31.2B | $8.40 | $7.31 | $1.09 |
| 07/15/2024 | Q2 | $12.4B | $31.3B | $8.62 | $8.40 | $0.22 |
| 04/15/2024 | Q1 | $12.9B | $32.1B | $11.58 | $8.64 | $2.94 |
| 01/16/2024 | Q4 | $10.9B | $29.1B | $5.48 | $4.27 | $1.21 |
| 10/17/2023 | Q3 | -- | $28.9B | $5.47 | -- | -- |
| 07/19/2023 | Q2 | -- | $26.6B | $3.08 | -- | -- |
| 04/18/2023 | Q1 | -- | $25.5B | $8.79 | -- | -- |
| 01/17/2023 | Q4 | -- | $23.5B | $3.32 | -- | -- |
| 10/18/2022 | Q3 | -- | $17.5B | $8.25 | -- | -- |
| 07/18/2022 | Q2 | -- | $13B | $7.73 | -- | -- |
| 04/14/2022 | Q1 | -- | $13.2B | $10.76 | -- | -- |
| 01/18/2022 | Q4 | -- | $13.4B | $10.81 | -- | -- |
| 10/15/2021 | Q3 | -- | $14.7B | $14.93 | -- | -- |
| 07/13/2021 | Q2 | -- | $16.6B | $15.02 | -- | -- |
| 04/14/2021 | Q1 | -- | $19.2B | $18.60 | -- | -- |
| 01/19/2021 | Q4 | -- | $15.6B | $12.08 | -- | -- |
| 10/14/2020 | Q3 | -- | $12.6B | $8.98 | -- | -- |
| 07/15/2020 | Q2 | -- | $15.3B | $0.55 | -- | -- |
| 04/15/2020 | Q1 | -- | $12.2B | $3.11 | -- | -- |
| 01/15/2020 | Q4 | -- | $14.2B | $4.69 | -- | -- |
| 10/15/2019 | Q3 | -- | $12.6B | $4.79 | -- | -- |
| 07/16/2019 | Q2 | -- | $14.2B | $5.81 | -- | -- |
| 04/15/2019 | Q1 | -- | $13.3B | $5.71 | -- | -- |
| 01/16/2019 | Q4 | -- | $12.2B | $6.04 | -- | -- |
| 10/16/2018 | Q3 | -- | $13B | $6.28 | -- | -- |
| 07/17/2018 | Q2 | -- | $13B | $5.98 | -- | -- |
| 04/17/2018 | Q1 | -- | $13.2B | $6.95 | -- | -- |
| 01/17/2018 | Q4 | -- | $11B | -$5.50 | -- | -- |
| 10/17/2017 | Q3 | -- | $11B | $5.02 | -- | -- |
| 07/18/2017 | Q2 | -- | $10.2B | $3.95 | -- | -- |
| 04/18/2017 | Q1 | -- | $9.5B | $5.15 | -- | -- |
| 01/18/2017 | Q4 | -- | $10.1B | $5.08 | -- | -- |
| 10/18/2016 | Q3 | -- | $10.1B | $4.88 | -- | -- |
| 07/19/2016 | Q2 | -- | $9.3B | $3.72 | -- | -- |
| 04/19/2016 | Q1 | -- | $7.3B | $2.68 | -- | -- |
| 01/20/2016 | Q4 | -- | $8.7B | $1.27 | -- | -- |
The Goldman Sachs Group, Inc. reported $32.2B worth of top line sales in its most recent quarter.
The Goldman Sachs Group, Inc. announced earnings per share of $12.25 which represents a beat of analyst forecast a $10.63 per share.
The Goldman Sachs Group, Inc. reported -- that represents -- per share over the last quarter.
The Goldman Sachs Group, Inc.'s earnings are forecast to grow from $40.54 per share to $37.10 per share next year representing an increase of 20.29%.
The Goldman Sachs Group, Inc.'s next earnings date is January 15, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.